These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 16413352

  • 1. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
    Bruder JM, Ma JZ, Basler JW, Welch MD.
    Urology; 2006 Jan; 67(1):152-5. PubMed ID: 16413352
    [Abstract] [Full Text] [Related]

  • 2. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ.
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [Abstract] [Full Text] [Related]

  • 3. [Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer].
    Deng J, Li W, Yang L, Wang L, Zou D.
    Zhonghua Nan Ke Xue; 2004 Oct; 10(10):761-3. PubMed ID: 15562791
    [Abstract] [Full Text] [Related]

  • 4. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.
    BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
    [Abstract] [Full Text] [Related]

  • 5. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK, Weston R, Mistry R, Parr NJ.
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [Abstract] [Full Text] [Related]

  • 6. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR.
    Cancer; 2004 Mar 01; 100(5):892-9. PubMed ID: 14983482
    [Abstract] [Full Text] [Related]

  • 7. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.
    Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.
    Urology; 2007 Mar 01; 69(3):500-4. PubMed ID: 17382153
    [Abstract] [Full Text] [Related]

  • 8. Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients.
    Deng JH, Yang LP, Wang LS, Zhou DF.
    Asian J Androl; 2004 Mar 01; 6(1):75-7. PubMed ID: 15064839
    [Abstract] [Full Text] [Related]

  • 9. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Mar 01; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 10. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
    Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT.
    Urology; 2007 Jul 01; 70(1):122-6. PubMed ID: 17656221
    [Abstract] [Full Text] [Related]

  • 11. The relationship between daily calcium intake and bone mineral density in men with prostate cancer.
    Planas J, Morote J, Orsola A, Salvador C, Trilla E, Cecchini L, Raventós CX.
    BJU Int; 2007 Apr 01; 99(4):812-5; discussion 815-6. PubMed ID: 17378843
    [Abstract] [Full Text] [Related]

  • 12. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
    Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, Yamamoto S, Yonese J, Fukui I, Takahashi S, Hatake K, Habuchi T.
    Urology; 2010 May 01; 75(5):1131-7. PubMed ID: 20163839
    [Abstract] [Full Text] [Related]

  • 13. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.
    Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL.
    Cancer; 2002 Nov 15; 95(10):2136-44. PubMed ID: 12412167
    [Abstract] [Full Text] [Related]

  • 14. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S.
    Cancer; 2009 Aug 01; 115(15):3468-74. PubMed ID: 19484786
    [Abstract] [Full Text] [Related]

  • 15. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
    Rodrigues P, Hering FO, Bruna P, Meller A, Afonso Y.
    Int J Urol; 2007 Apr 01; 14(4):317-20. PubMed ID: 17470161
    [Abstract] [Full Text] [Related]

  • 16. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.
    Ann Pharmacother; 2006 Dec 01; 40(12):2107-14. PubMed ID: 17132807
    [Abstract] [Full Text] [Related]

  • 17. Bone mineral density in rural Thai adults living in Khon Kaen province.
    Pongchaiyakul C, Rojroongwasinkul N, Chotmongkol R, Kosulwat V, Charoenkiatkul S, Rajatanavin R.
    J Med Assoc Thai; 2002 Feb 01; 85(2):235-44. PubMed ID: 12081125
    [Abstract] [Full Text] [Related]

  • 18. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.
    Bruder JM, Ma JZ, Wing N, Basler J, Katselnik D.
    J Clin Densitom; 2006 Feb 01; 9(4):431-7. PubMed ID: 17097529
    [Abstract] [Full Text] [Related]

  • 19. Peripheral or axial bone density measurements to identify osteoporosis in prostate cancer patients undergoing androgen deprivation therapy?
    Wadhwa VK, Parr NJ.
    Urology; 2009 Jun 01; 73(6):1347-51. PubMed ID: 19362345
    [Abstract] [Full Text] [Related]

  • 20. The role of distal third radius dual energy X-ray absorptiometry (DXA) and central DXA in evaluating for osteopenia and osteoporosis in men receiving androgen deprivation therapy for prostate cancer.
    Sieber PR, Rommel FM, Theodoran CG, Russinko PJ, Woodward CA, Schimke L.
    J Clin Densitom; 2012 Jun 01; 15(3):351-4. PubMed ID: 22542224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.